Abbott Laboratories (NYSE:ABT) Raised to Buy at Rothschild & Co Redburn

Abbott Laboratories (NYSE:ABT) was upgraded by investment analysts at Rothschild & Co Redburn from a “neutral” rating to a “buy” rating in a research report issued on Friday, Benzinga reports. The brokerage presently has a $127.00 target price on the healthcare product maker’s stock, up from their previous target price of $119.00. Rothschild & Co Redburn’s target price indicates a potential upside of 31.45% from the company’s current price.

ABT has been the subject of a number of other reports. Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, BTIG Research upped their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $119.80.

Abbott Laboratories Trading Down 2.2%

NYSE ABT opened at $96.61 on Friday. The firm’s fifty day moving average is $107.10 and its two-hundred day moving average is $98.68. Abbott Laboratories has a one year low of $81.97 and a one year high of $135.37. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market cap of $167.18 billion, a PE ratio of 31.27, a P/E/G ratio of 1.83 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. First Financial Bank Trust Division increased its holdings in shares of Abbott Laboratories by 2.2% in the 3rd quarter. First Financial Bank Trust Division now owns 102,483 shares of the healthcare product maker’s stock valued at $10,128,000 after purchasing an additional 2,180 shares in the last quarter. Burkett Financial Services LLC boosted its stake in shares of Abbott Laboratories by 22.0% during the 3rd quarter. Burkett Financial Services LLC now owns 1,742 shares of the healthcare product maker’s stock worth $172,000 after acquiring an additional 314 shares in the last quarter. Hickory Point Bank & Trust grew its holdings in shares of Abbott Laboratories by 20.7% in the 3rd quarter. Hickory Point Bank & Trust now owns 1,749 shares of the healthcare product maker’s stock worth $173,000 after acquiring an additional 300 shares during the period. State Street Corp increased its stake in Abbott Laboratories by 1.7% in the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Finally, Premier Financial Group purchased a new stake in Abbott Laboratories during the second quarter worth $118,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.